Studies on Formulations from a Clinical Perspective

Abstract

This review highlights the author’s research conducted at Mukogawa Women’s University from April 2002 to March 2024. The work is categorized into following three areas: (1) Evaluation of the bitterness of oral medications using a taste sensor, (2) Development of drug delivery systems utilizing poly(lactic-co-glycolic acid) (PLGA), and (3) Clinical pharmaceutical evaluation of various injectable formulations. In section (1), the bitterness of oral medications, both alone and in combination with food or beverages, was quantitatively assessed. The taste sensor demonstrated high predictive accuracy, with a significant correlation observed between the sensor’s bitter-sensitive outputs and the human taste receptor hT2R14, as documented in BitterDB. Recently, an innovative taste sensor featuring lipid/polymer membranes modified with 2,6-dihydroxybenzoic acid (2,6-DHBA), based on an allosteric mechanism, was developed to improve the detection of bitterness in non-charged compounds. In section (2), PLGA microspheres were engineered for the sustained release of prostaglandin derivatives over one month. Furthermore, polymeric micelles under 100 nm in diameter, composed of PLGA and LL-12 (a mutated fragment of human cathelicidin peptide), exhibited potent antibacterial activity and inhibited the proliferation of various cancer cells. Section (3) focuses on injectable formulations, including the development of a quantitative predictive system to evaluate the risk of insoluble particle formation when mixing ceftriaxone with calcium-containing injections. Additionally, the use of minimum inhibitory concentration (MIC) values and nomograms was explored to predict the clinical efficacy of imipenem derivatives. This research significantly contributes to enhancing the safety and efficacy of clinical treatments for patients.